Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Viardot

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Trials|January 3, 2023
Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studiesMax Topp, Monika Dlugosz-Danecka, Aleksander B Skotnicki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study groupMichael Pfreundschuh, Viola Poeschel, Samira Zeynalova, et al.
Oncotarget|June 19, 2014
Potential clinical implications of BRAF mutations in histiocytic proliferationsAnna-Maria Bubolz, Stephanie E Weissinger, Albrecht Stenzinger, et al.
Blood|July 1, 2011
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantationNicola Gökbuget, Nadezda Basara, Herrad Baurmann, et al.
Blood|May 18, 2012
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomabMatthias Klinger, Christian Brandl, Gerhard Zugmaier, et al.
Science (New York, N.Y.)|August 16, 2008
Tumor regression in cancer patients by very low doses of a T cell-engaging antibodyRalf Bargou, Eugen Leo, Gerhard Zugmaier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemiaMax S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2026
Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO TrialMatthew Matasar, Zhiming Li, Theodoros P Vassilakopoulos, et al.
Investigational New Drugs|March 16, 2020
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Blood|April 12, 2012
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationNicola Gökbuget, Daniel Stanze, Joachim Beck, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Trials|January 3, 2023
Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studiesMax Topp, Monika Dlugosz-Danecka, Aleksander B Skotnicki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study groupMichael Pfreundschuh, Viola Poeschel, Samira Zeynalova, et al.
Oncotarget|June 19, 2014
Potential clinical implications of BRAF mutations in histiocytic proliferationsAnna-Maria Bubolz, Stephanie E Weissinger, Albrecht Stenzinger, et al.
Blood|July 1, 2011
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantationNicola Gökbuget, Nadezda Basara, Herrad Baurmann, et al.
Blood|May 18, 2012
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomabMatthias Klinger, Christian Brandl, Gerhard Zugmaier, et al.
Science (New York, N.Y.)|August 16, 2008
Tumor regression in cancer patients by very low doses of a T cell-engaging antibodyRalf Bargou, Eugen Leo, Gerhard Zugmaier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemiaMax S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2026
Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO TrialMatthew Matasar, Zhiming Li, Theodoros P Vassilakopoulos, et al.
Investigational New Drugs|March 16, 2020
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Blood|April 12, 2012
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationNicola Gökbuget, Daniel Stanze, Joachim Beck, et al.
Pageof 9